UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Da	te of Report (date of earliest event reported)): February 9, 2022
Delaware (State or other jurisdiction of incorporation or organization)	001-35020 (Commission File Number)	20-3341405 (I.R.S. Employer Identification Number)
	3851 West Hamlin Road Rochester Hills, Michigan 483	09
	(Address of principal executive offices)	(Zip Code)
	(248) 291-1210	
	(Registrant's telephone number, including	g area code)
	Not Applicable	
(Former Name or Former Address, if Changed S	Since Last Report)
Soliciting material pursuant to Rule 14a-12 ur Pre-commencement communications pursuar Pre-commencement communications pursuar	nder the Exchange Act (17 CFR 240.14a-12) at to Rule 14d-2(b) under the Exchange Act (17 at to Rule 13e-4(c) under the Exchange Act (17	CFR 240.13e-4(c))
Title of Feeb Class	Trading Symbol(s)	Name of Each Exchange on which Registered
	• • • • • • • • • • • • • • • • • • • •	NYSE American LLC
ecurities Exchange Act of 1934 (§240.12b-2 of the derging growth company an emerging growth company, indicate by check	his chapter). k mark if the registrant has elected not to use	
	(State or other jurisdiction of incorporation or organization) the appropriate box below if the Form 8-K filing Written communications pursuant to Rule 42 Soliciting material pursuant to Rule 14a-12 u Pre-commencement communications pursuant Pre-commencement communications pursuant Pre-commencement communications pursuant Securities Each Class Title of Each Class Tommon Stock, par value \$.0001 per share licate by check mark whether the registrant is an ecurities Exchange Act of 1934 (§240.12b-2 of the terging growth company □ an emerging growth company, indicate by check	(State or other jurisdiction of incorporation or organization) 3851 West Hamlin Road Rochester Hills, Michigan 483 (Address of principal executive offices) (248) 291-1210 (Registrant's telephone number, including Not Applicable (Former Name or Former Address, if Changed States of Principal executive offices) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 Securities registered pursuant to Section 12(b) Title of Each Class Trading Symbol(s) Title of Each Class Trading Symbol(s) INFU icate by check mark whether the registrant is an emerging growth company as defined in Rule 4 eccurities Exchange Act of 1934 (§240.12b-2 of this chapter).

Item 7.01 - Regulation FD

On February 9, 2022, InfuSystem Holdings, Inc. (the "Company") issued a press release announcing that the Company will disclose its preliminary financial results for the fourth quarter and fiscal year 2021 on Thursday, February 10, 2022 before the market opens. The Company will also conduct a conference call for all interested investors on Thursday, February 10, 2022 at 9:00 a.m. Eastern Time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 7.01 — "Regulation FD Disclosure" of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release of InfuSystem Holdings, Inc. dated February 9, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

By: /s/ Richard DiIorio

Richard DiIorio

Chief Executive Officer and Director

Dated: February 9, 2022



InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210

FOR IMMEDIATE RELEASE

CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700

InfuSystem to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022

Investor Conference Call to be held 9:00 a.m. Eastern Time

Rochester Hills, Michigan, February 9, 2022 — InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue preliminary fourth quarter and full year 2021 financial results on Thursday, February 10, 2022, before the market opens.

The Company will also conduct a conference call for all interested parties on Thursday, February 10, 2022 at 9:00 a.m. Eastern Time to discuss its financial results.

To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company's website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, replay access code 8622274 through Thursday, February 17, 2022.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services ("ITS"), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services ("DME Services"), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.